Abstract:Over the past few decades, substantial evidence has convincingly revealed the existence of cancer stem cells (CSCs) as a minor subpopulation in cancers, contributing to an aberrantly high degree of cellular heterogeneity within the tumor. CSCs are functionally defined by their abilities of self-renewal and differentiation, often in response to cues from their microenvironment. Biological phenotypes of CSCs are regulated by the integrated transcriptional, post-transcriptional, metabolic, and epigenetic regulatory networks. CSCs contribute to tumor progression, therapeutic resistance, and disease recurrence through their sustained proliferation, invasion into normal tissue, promotion of angiogenesis, evasion of the immune system, and resistance to conventional anticancer therapies. Therefore, elucidation of the molecular mechanisms that drive cancer stem cell maintenance, plasticity, and therapeutic resistance will enhance our ability to improve the effectiveness of targeted therapies for CSCs. In this review, we highlight the key features and mechanisms that regulate CSC function in tumor initiation, progression, and therapy resistance. We discuss factors for CSC therapeutic resistance, such as quiescence, induction of epithelial-to-mesenchymal transition (EMT), and resistance to DNA damage-induced cell death. We evaluate therapeutic approaches for eliminating therapy-resistant CSC subpopulations, including anticancer drugs that target key CSC signaling pathways and cell surface markers, viral therapies, the awakening of quiescent CSCs, and immunotherapy. We also assess the impact of new technologies, such as single-cell sequencing and CRISPR-Cas9 screening, on the investigation of the biological properties of CSCs. Moreover, challenges remain to be addressed in the coming years, including experimental approaches for investigating CSCs and obstacles in therapeutic targeting of CSCs.

DNA Replication Licensing Factors: Novel Targets for Cancer Therapy via Inhibiting the Stemness of Cancer Cells

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Prospect of reprogramming replication licensing for cancer drug development

DNA Replication: Mechanisms and Therapeutic Interventions for Diseases

Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic

Mechanisms For Stalled Replication Fork Stabilization: New Targets For Synthetic Lethality Strategies In Cancer Treatments

Epigenetic Regulation of Cancer Stem Cells: Shedding Light on the Refractory/relapsed Cancers

Implications of ubiquitination and the maintenance of replication fork stability in cancer therapy

Targeting replication stress in cancer therapy

Drug Resistance of Tumor Stem Cells and Strategy of Therapy

Mechanism-based Suppression of Cancer by Targeting DNA-Replicating Enzymes

Beyond Regulations at DNA Levels: A Review of Epigenetic Therapeutics Targeting Cancer Stem Cells

Ott_a_224465 525..540

Drug resistance and Cancer stem cells

Stem cell programs in cancer initiation, progression, and therapy resistance

Cancer Stem Cell Theory: Therapeutic Implications for Nanomedicine.

Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment

Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers

Defective Replication Stress Response is Inherently Linked to the Cancer Stem Cell Phenotype.

Emerging Cancer Therapeutic Opportunities Target DNA-repair Systems

Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents